Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014

About this resource:

HHS Non-systematic Review

Source: National Heart, Lung, and Blood Institute

Last Reviewed: September 2014

Workgroups: Blood Disorders and Blood Safety Workgroup

This report provides recommendations to help primary care providers and other clinicians, nurses, and staff make decisions about the treatment and care of people with sickle cell disease. It includes guidelines related to:

  • Routine health maintenance
  • Recognition and treatment of common complications
  • Prescribing  and monitoring hydroxyurea and blood transfusion therapy
Read more about this resource

Objectives related to this resource (1)

Increase the proportion of people with sickle cell disease on Medicare who received disease-modifying therapies — BDBS‑02
Baseline only

Suggested Citation

1.

National Institutes of Health, National Heart, Lung, and Blood Institute. (2014). Evidence-based management of sickle cell disease: expert panel report, 2014. Retrieved from https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease